Patient-Derived Organoids Predict Chemoradiation Responses of Locally Advanced Rectal Cancer

Ye Yao, Xiaoya Xu, Lifeng Yang, Ji Zhu, Juefeng Wan, Lijun Shen, Fan Xia, Guoxiang Fu, Yun Deng, Mengxue Pan, Qiang Guo, Xiaoxue Gao, Yuanchuang Li, Xinxin Rao, Yi Zhou, Liping Liang, Yaqi Wang, Jing Zhang, Hui Zhang, Guichao LiLixing Zhang, Junjie Peng, Sanjun Cai, Chen Hu, Jianjun Gao, Hans Clevers, Zhen Zhang, Guoqiang Hua

Research output: Contribution to journal/periodicalArticleScientificpeer-review

313 Citations (Scopus)


Accumulating evidence indicates that patient-derived organoids (PDOs) can predict drug responses in the clinic, but the ability of PDOs to predict responses to chemoradiation in cancer patients remains an open question. Here we generate a living organoid biobank from patients with locally advanced rectal cancer (LARC) treated with neoadjuvant chemoradiation (NACR) enrolled in a phase III clinical trial. Our co-clinical trial data confirm that rectal cancer organoids (RCOs) closely recapitulate the pathophysiology and genetic changes of corresponding tumors. Chemoradiation responses in patients are highly matched to RCO responses, with 84.43% accuracy, 78.01% sensitivity, and 91.97% specificity. These data imply that PDOs predict LARC patient responses in the clinic and may represent a companion diagnostic tool in rectal cancer treatment.

Original languageEnglish
Pages (from-to)17-26.e6
JournalCell Stem Cell
Issue number1
Publication statusPublished - 02 Jan 2020


Dive into the research topics of 'Patient-Derived Organoids Predict Chemoradiation Responses of Locally Advanced Rectal Cancer'. Together they form a unique fingerprint.

Cite this